---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053849"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2026-08-06T11:33:12+00:00"
generated_at: "2026-08-06T11:35:16.400296+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Collegium Q2 net revenue $199.9M (+6% YoY); GAAP loss $0.46; guidance cut on total revenue and EBITDA

## Summary
- Q2 net revenue $199.9M, up 6% YoY; GAAP net loss $15.1M ($0.46 loss per share) vs prior year net income $12.0M.
- Non-GAAP adjusted net income $75.4M ($1.92 adj EPS); Adjusted EBITDA $113.8M, up 8% YoY.
- JORNAY PM revenue $46.1M (+41% YoY); AZSTARYS revenue $12.9M (partial quarter after May 12 acquisition close).
- Full-year 2026 guidance: Product Revenues $825-855M (down from $865-895M); AZSTARYS raised to $65-75M; Adjusted EBITDA $445-470M (down from $475-500M).
- Completed acquisition of AZSTARYS from Corium Therapeutics; board appointed Michael Donovan; HQ relocation to Boston planned for Q1 2027.

## SEC filing metadata
- accession: 0001628280-26-053849
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2026-08-06T11:33:12+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/0001628280-26-053849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/coll-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053849
- JSON: https://secwatch.observer/filing/0001628280-26-053849.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.